Cost-effectiveness evaluation of newborn hemoglobinopathy screening from the perspective of state health care systems

Early Human Development

Volumn 45, Issue 3, 1996, Pages 257-275

  Gessner, Bradford D ^a   Teutsch, Steven M ^b   Shaffer, Phaedra A ^b  

^a Alaska Division of Public Health   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Cost effectiveness; Hemoglobinopathies; Neonatal screening; Sickle cell anemia

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEMOGLOBINOPATHY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INFANT; MEDICAL DECISION MAKING; NEWBORN; NEWBORN SCREENING; PRESCHOOL CHILD; PREVALENCE; RACE; SCREENING TEST; SICKLE CELL ANEMIA; UNITED STATES;

EID: 0030200497     PISSN: 03783782     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-3782(96)01761-6     Document Type: Article

References (68)

1. [1] Consensus conference. Newborn screening for sickle cell disease and other hemoglobinopathies. JAMA 1987; 258: 1205.
2. [2] Newborn screening for sickle cell disease and other hemoglobinopathies. National Institutes of Health Consensus Development Conference Statement; Vol. 6, No. 9; 1987. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, MD.
3. [3] Tsevat J, Wong JB, Pauker SG, Steinberg MH, Neonatal screening for sickle cell disease: a cost-effectiveness analysis. J Pediatr 1991; 118: 546.
4. [4] Sprinkle RH, Hynes DM, Konrad TR. Is universal neonatal hemoglobinopathy screening cost-effective? Arch Pediatr Adolesc Med 1994; 148: 461.
5. [5] Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N Engl J Med 1986; 314: 1593.
6. [6] Vichinsky E, Hurst D, Earles A, et al. Newborn screening for sickle cell disease: effect on mortality. Pediatrics 1988; 81: 749.
7. [7] Emond AM, Collis R, Darvill D, et al. Acute splenic sequestration in homozygous sickle cell disease: natural history and management. J Pediatr 1985; 107: 201.
8. [8] Bainbridge R, Higgs DR, Maude GH, Serjeant GR. Clinical presentation of homozygous sickle cell disease. J Pediatr 1985; 106: 881.
9. [9] Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med 1994; 330: 1639.
10. [10] Lotus Development Corporation. Lotus 123 Spreadsheet for Windows, release 4. Cambridge MA, 1993.
11. [11] Sickle cell disease: screening, diagnosis, management, and counseling in newborns and infants. Clinical Practice Guideline number 6. U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. Rockville, Maryland. 1993.
12. [12] Powars D. Diagnosis at birth improves survival of children with sickle cell anemia. Pediatrics 1989; 83 (suppl): 830.
13. [13] Rosenthal MA, Ou CN, Hoffman W, et al. Monoclonal antibody immunoassay for the identification of hemoglobin variants in neonatal screening. Screening 1994; 3: 67.
14. [14] Nussbaum RL, Powell C, Graham HL, et al. Newborn screening for sickling hemoglobinopathies. Houston, 1976 to 1980. Am J Dis Child 1984; 138: 44.
15. [15] Neal-Cooper F, Scott RB. Genetic counseling in sickle cell anemia: experiences with couples at risk. Public Health Rep 1988: 103: 174.
16. [16] Fost N. Ethical implications of screening asymptomatic individuals. FASEB J 1992; 6: 2813.
17. [17] Warkany J. Prevention of congenital malformations. Teratology 1981; 23: 175
18. [18] Leonard CO, Chase GA, Childs B. Genetic counseling: a consumers' view. N Engl J Med 1972; 287: 433.
19. [19] Fost N. Kaback MM. Why do sickle screening in children? The trait is the issue. Pediatrics 1973; 51: 742.
20. [20] Schoen EJ, Marks SM, Clemons MM, Bachman RP. Comparing prenatal and neonatal diagnosis of hemoglobinopathies. Pediatrics 1993; 92: 354.
21. [21] Miller ST, Stilerman TV, Rao SP, et al. Newborn screening for sickle cell disease: when is an infant 'lost to follow-up'? Am J Dis Child 1990; 144: 1343.
22. [22] Listernick R, Frisone L, Silverman BL. Delayed diagnosis of infants with abnormal neonatal screens. JAMA 1992; 267: 1095.
23. [23] Buchanan GR, Siegel JD, Smith SS, et al. Oral penicillin prophylaxis in children with impaired splenic function: a study of compliance. Pediatrics 1982; 70: 926.
24. [24] Buchanan GR, Smith SJ. Pneumococcal septicemia despite pneumococcal vaccine and prescription of penicillin in children with sickle cell anemia. Am J Dis Child 1986; 140: 428.
25. [25] Nottidge VA. Pneumococcal meningitis in sickle cell disease in childhood. Am J Dis Child 1983; 137: 29.
26. [26] Roberts T, Frenkel JK. Estimating income losses and other preventable costs caused by congenital toxoplasmosis in people in the United States. J Am Vet Med Assoc 1990; 196: 249.
27. [27] Henderson JB, Beattie CP, Hale EG, Wright T. The evaluation of new services: possibilities for preventing congenital toxoplasmosis. Int J Epidemiol 1984; 13: 65.
28. [28] Newborn screening report: 1990. Council of Regional Networks for Genetic Services. February 1992.
29. [29] Gardner RV, Keitt A. University of Florida sickle cell screening program for neonates: design and results. J Natl Med Assoc 1988; 80: 273.
30. [30] Therrell BL, Simmank JL, Wilborn M. Experiences with sickle hemoglobin testing in the Texas newborn screening program. Pediatrics 1989; 83 (suppl): 864.
31. [31] Hurst D. Northern California's experience. Pediatrics 1989; 83 (suppl): 868.
32. [32] Harris MS, Eckman JR. Georgia's experience with newborn screening: 1981 to 1985. Pediatrics 1989: 83 (suppl): 858.
33. [33] U.S. Bureau of the Census (1992). Statistical abstract of the United States: 1992 (112 ed.). Washington DC: U.S. Department of Commerce.
34. [34] Lane PA, Eckman JR. Letter to the editor. J Pediatr 1992; 120: 162.
35. [35] Tsevat J, Wong JB, Pauker SG, Steinberg MH. Letter to the editor. Pediatrics 1992; 120: 163.
36. [36] Fost N. Ethical issues in genetics. Pediatr Clin North Am 1992; 39: 79.
37. [37] Holtzman NA. The diffusion of new genetic tests for predicting disease. FASEB J 1992; 6: 2806.
38. [38] Wertz DC. Ethical and legal implications of the new genetics: issues for discussion. Soc Sci Med 1992; 35: 495.
39. [39] Andrews LB, Jaeger AS. Confidentiality of genetic information in the workplace. Amer J Law Med 1991; 17: 75.
40. [40] Billings P, Beckwith J. Genetic testing in the workplace: a view from the USA. Trends Genet 1992; 8: 198.
41. [41] Billings PR, Kohn MA, de Cuevas M, Beckwith J, Alper JS, Natowicz MR. Discrimination as a consequence of genetic testing. Am J Hum Genet 1992; 50: 476.
42. [42] Bowman JE. Legal and ethical issues in newborn screening. Pediatrics 1989; 83(suppl): 894.
43. [43] Fost N. Genetic diagnosis and treatment: ethical considerations. Am J Dis Child 1993; 147: 1190.
44. [44] Charo RA. Legal and regulatory issues surrounding carrier testing. Clin Obstet Gynecol 1993; 36: 568.
45. [45] McEwen JE, Reilly PR. State legislative efforts to regulate use and potential misuse of genetic information. Am J Hum Genet 1992; 51: 637.
46. [46] Pomeroy SL, Holmes SJ, Dodge PR, Feigin RD. Seizures and other neurologic sequelae of bacterial meningitis in children. N Engl J Med 1990; 323: 1651.
47. [47] Schaad UB. Lips U, Gnehm HE, et al. Dexamethasone therapy for bacterial meningitis in children. Lancet 1993; 342: 457.
48. [48] Odio CM, Faingezicht I, Paris M, et al. The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. N Engl J Med 1991; 324: 1525.
49. [49] Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. New York: Oxford University Press, 1993.
50. [50] Powars DR, Overturf G, Weiss J, et al. Pneumococcal septicemia in children with sickle cell anemia: changing trend of survival. JAMA 1981; 245: 1839.
51. [51] Gill FM, Brown A, Gallagher D, et al. Newborn experience in the cooperative study of sickle cell disease. Pediatrics 1989; 83 (suppl): 827.
52. [52] Powars DR. Natural history of sickle cell disease - the first ten years. Semin Hematol 1975; 12: 267.
53. [53] Leikin SL, Gallagher D, Kinney TR, et al. Mortality in children and adolescents with sickle cell disease. Pediatrics 1989; 84: 500.
54. [54] Rasmussen N, Johnsen NJ, Bohr VA. Otologic sequelae after pneumococcal meningitis: a survey of 164 consecutive cases with a follow-up of 94 survivors. Laryngoscope 1991; 101: 876.
55. [55] Dodge PR, Davis H, Feigin RD, et al. Prospective evaluation of hearing impairment as a sequela of acute bacterial meningitis. N Engl J Med 1984; 311: 869.
56. [56] Vienny H, Despland PA, Lutschg J, Deonna T, Dutoit-Marco ML, Gander C. Early diagnosis and evolution of deafness in childhood bacterial meningitis: a study using brainstem auditory evoked potentials. Pediatrics 1984; 73: 579.
57. [57] Letson GW, Gillin BG, Bulkow LR, Parks DJ, Ward JI. Severity and frequency of sequelae of bacterial meningitis in Alaska Native children. Am J Dis Child 1992; 146: 560.
58. [58] Bohr V, Rasmussen N, Hansen B, et al. Pneumococcal meningitis: an evaluation of prognostic factors in 164 cases based on mortality and a study of lasting sequelae. J Infect 1985; 10: 143.
59. [59] Schaad UB, Suter S, Gianella-Borradori A, et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med 1990; 322: 141.
60. [60] Peltola H, Anttila M, Renkonen O, and the Finnish study group. Randomized comparison of chloramphenicol, ampicillin, cefotaxime, and ceftriaxone for childhood bacterial meningitis. Lancet 1989; 1: 1281.
61. [61] Jadavji T, Biggar WD, Gold R, Prober CG. Sequelae of acute bacterial meningitis in children treated for seven days. Pediatrics 1986; 78: 21.
62. [62] Topley JM, Rogers DW, Stevens MCG, Serjeant GR. Acute splenic sequestration and hypersplenism in the first five years in homozygous sickle cell disease. Arch Dis Child 1981; 56: 765.
63. [63] O'Brien RT, McIntosh S, Aspnes GT, Pearson HA. Prospective study of sickle cell anemia in infancy. J Pediatr 1976; 89: 205.
64. [64] Warren NS, Carter TP, Humbert JR, Rowley PT. Newborn screening for hemoglobinopathies in New York State, Experience of physicians and parents of affected children. J Pediatr 1982; 100: 373.
65. [65] Githens JH, Lane PA, McCurdy RS, Houston ML, McKinna JD, Cole DM. Newborn screening for hemoglobinopathies in Colorado: the first 10 years. Am J Dis Child 1990; 144: 466.
66. [66] Yorke D, Mitchell J, Clow C, et al. Newborn screening for sickle cell and other hemoglobinopathies: a Canadian pilot study. Clin Invest Med 1992; 15: 376.
67. [67] Florida's cost/implementation study for public law 99-457, part H, infants and toddlers: phase II findings. Submitted to: the Florida Department of Education, Bureau of Education for Exceptional Students, and the Florida Interagency Coordinating Council for Infants and Toddlers. July, 1991.
68. [68] Kesler K, Kesler M. Cost identification of children with special health care needs and developmental delays enrolled in the community placement program under the Division of Mental Health and Developmental Disabilities in Alaska. Prepared as partial fulfillment of requirements for M.P.H., University of California, Berkeley, CA, May, 1993.